3 things to expect from Novavax in 2021

This may be the year of revenue.

| More on:
covid vaccine shares represented by numbers 2021 with the one displayed as syringe

Image source: Getty Images

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Novavax Inc (NASDAQ: NVAX) shares gained more than 2,600% last year as the clinical-stage biotech became one of the front-runners in the race to develop a coronavirus vaccine -- and was awarded $1.6 billion from the United States Government to support its efforts.

That was a genuinely amazing performance, and as 2021 begins, Novavax still has a lot on its agenda. Here are three things investors should be looking for from the company this year.

1. A possible coronavirus vaccine -- and revenue

Novavax has a late-stage clinical trial for its coronavirus vaccine candidate, NVX-CoV2373, well underway in the United Kingdom, and could be ready to report interim data from it early in the current quarter. If that data is positive, the company will use it to support its submissions to various major healthcare regulators.

Regulatory agencies granted emergency use authorizations for the COVID-19 vaccines of Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) within weeks of their phase 3 interim reports. If Novavax's fortunes are similar, the company could begin generating vaccine revenue in the first half of 2021. NVX-CoV2373 would be its first marketed product -- a huge step for the company.

2. A NanoFlu regulatory submission

Last spring, Novavax reported that its flu vaccine candidate met all primary endpoints in a pivotal trial. Later in the year, the company assembled a team of experts to shepherd NanoFlu through the regulatory approval process.

Novavax hasn't said when it will submit its application for NanoFlu to the Food and Drug Administration. But it did say it would apply to have that vaccine reviewed under the FDA's accelerated approval pathway. It's possible a submission could happen at some point this year.

3. Progress on a combined coronavirus/flu vaccine

In October, Novavax said it would begin exploring the possibility of producing a single shot that combines both its coronavirus and flu vaccines. The company said any such dual-purpose product would be for post-pandemic use. Novavax didn't provide other timeline details. But we could imagine that it may report preclinical data or other early details on this project this year.

Positive results on any of the fronts listed above could provide a catalyst for Novavax's shares. So even though its 2020 stock price gain was massive, there's room for additional good news to drive this biotech company even higher.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of August 16th 2021

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News